Related references
Note: Only part of the references are listed.Effect of Empagliflozin on Erythropoietin Levels, Iron Stores, and Red Blood Cell Morphology in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease
C. David Mazer et al.
CIRCULATION (2020)
Mediators of the Effects of Canagliflozin on Heart Failure in Patients With Type 2 Diabetes
JingWei Li et al.
JACC-HEART FAILURE (2020)
Empagliflozin in Heart Failure Diuretic and Cardiorenal Effects
Matthew Griffin et al.
CIRCULATION (2020)
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
J. J. V. McMurray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Medical Therapy for Heart Failure With Reduced Ejection Fraction
Stephen J. Greene et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial
Silvio E. Inzucchi et al.
DIABETES CARE (2018)
2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America
Clyde W. Yancy et al.
CIRCULATION (2017)
Influence of Previous Heart Failure Hospitalization on Cardiovascular Events in Patients With Reduced and Preserved Ejection Fraction
Natalie A. Bello et al.
CIRCULATION-HEART FAILURE (2014)
Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure
Scott D. Solomon et al.
CIRCULATION (2007)
Share Paper
